… The consensus that has emerged among investigators is that surmounting the cancer
therapeutic problem will be greatly facilitated by an in-depth understanding of the molecular …

… is inhibition of its catalytic activity with small-molecule inhibitors. Examples of successful
therapeutic intervention by use of RTK inhibitors … cell lung cancers with mutant EGFR. Sunitinib …

… These various factors are all potential targets for therapeutic … Inhibiting these pathways
with specific inhibitors or activating … This type of HDAC inhibitor could be of therapeutic value …

… , and exemplified by the vascular endothelial growth factor (VEGF)-targeted antibody
Avastin and small-molecule inhibitors of VEGF receptor tyrosine kinases such as Nexavar (…

… The combination of avelumab and axitinib, a VEGF receptor inhibitor, has been evaluated
in a phase IB treatment-naive patients with advanced renal cell carcinoma [78]. The doublet …

… cancer cell phenotype. Estimated spending on research and development of anti-cancer
therapeutic … In the same year, the USFDA approved gefitinib, a tyrosine kinase receptor inhibitor …

… Targeting ligands versus receptors … one target a receptor or its ligand when developing
a cancer therapeutic? One consideration is whether inhibition of the ligand or the receptor will …

… status of a variety of angiogenesis inhibitors (see reviews, Ref. [… receptors (VEGFR), and
our efforts to develop neutralizing anti-VEGFR antibodies as antiangiogenic cancer therapeutic …

… kinase inhibitors and provide classification of the inhibitors according … inhibitors, ATP
competitive inhibitors, protein substrate competitive inhibitors, and covalent bond forming inhibitors. …

… , a major antiapoptotic pathway in cancer cells and cardiomyocytes, that inhibits proapoptotic
factors FOXO3a and Bad. This culminates in potent inhibition of apoptosis in CML cells. …